1-[4-(二甲氨基)苯基]-2-甲基丙烷-1-酮 | 4278-79-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-[4-(二甲氨基)苯基]-2-甲基丙烷-1-酮
• 英文名称: 1-(4-(dimethylamino)phenyl)-2-methylpropan-1-one
• 英文别名: 1-[4-(dimethylamino)phenyl]-2-methylpropan-1-one
• CAS: 4278-79-9
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: PCCMMAUTWSOKRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2922399090
• 危险标志：
  GHS07
• 危险性描述：
  H317
• 危险性防范说明：
  P280

反应信息

• 作为反应物：
  描述：

  1-[4-(二甲氨基)苯基]-2-甲基丙烷-1-酮 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 0.75h， 生成 1-(4-(dimethylamino)phenyl)-2-methylpropan-1-ol
  参考文献：
  名称：

  Knauer, Birgit; Krohn, Karsten, Liebigs Annalen, 1995, # 4, p. 677 - 684

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-Dimethylamino-phenyl)-3-methyl-2-trimethylsilanyloxy-butyronitrile 生成 1-[4-(二甲氨基)苯基]-2-甲基丙烷-1-酮
  参考文献：
  名称：

  DEUCHERT K.; HERTENSTEIN U.; HUENIG S.; WEHNER G., CHEM. BER., 1979, 112, NO 6, 2045-2061

  摘要：

  DOI：

文献信息

• Rhodium-Catalyzed Ketone Methylation Using Methanol Under Mild Conditions: Formation of α-Branched Products
  作者：Louis K. M. Chan、Darren L. Poole、Di Shen、Mark P. Healy、Timothy J. Donohoe

  DOI：10.1002/anie.201307950

  日期：2014.1.13

  The rhodium‐catalyzed methylation of ketones has been accomplished using methanol as the methylating agent and the hydrogen‐borrowing method. The sequence is notable for the relatively low temperatures that are required and for the ability of the reaction system to form α‐branched products with ease. Doubly alkylated ketones can be prepared from methyl ketones and two different alcohols by using a

  使用甲醇作为甲基化剂和借氢方法完成了铑催化的酮的甲基化。该序列的显着之处在于所需的温度相对较低，并且反应系统能够轻松形成 α 支化产物。双烷基化酮可以通过使用连续的一锅铱和铑催化工艺由甲基酮和两种不同的醇制备。
• [EN] LINKED DIBENZIMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DU DIBENZIMIDAZOLE LIÉS
  申请人：ENANTA PHARM INC

  公开号：WO2010091413A1

  公开（公告）日：2010-08-12

  The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了联苯二咪唑衍生物，或其药学上可接受的盐、酯或前药，其抑制含RNA的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2010099527A1

  公开（公告）日：2010-09-02

  The present invention discloses compounds or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了抑制RNA含病毒，特别是丙型肝炎病毒（HCV）的化合物或药用可接受的盐、酯或前药，因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Experimental and Computational Studies of Palladium-Catalyzed Spirocyclization via a Narasaka–Heck/C(sp³ or sp²)–H Activation Cascade Reaction
  作者：Wan-Xu Wei、Yuke Li、Ya-Ting Wen、Ming Li、Xue-Song Li、Cui-Tian Wang、Hong-Chao Liu、Yu Xia、Bo-Sheng Zhang、Rui-Qiang Jiao、Yong-Min Liang

  DOI：10.1021/jacs.1c04114

  日期：2021.5.26

  es via a palladium-catalyzed tandem Narasaka–Heck/C(sp3 or sp2)–H activation reaction is reported here. The key step in this transformation is the activation of a δ-C–H bond via an in situ generated σ-alkyl-Pd(II) species to form a five-membered spiro-palladacycle intermediate. The concerted metalation-deprotonation (CMD) process, rate-determining step, and energy barrier of the entire reaction were

  本文报道了通过钯催化串联 Narasaka-Heck/C(sp 3或 sp 2 )-H 活化反应首次合成高应变螺环丁烷-吡咯啉。这种转变的关键步骤是通过原位生成的 σ-烷基-Pd(II) 物质激活 δ-C-H 键，形成五元螺-钯环中间体。通过密度泛函理论（DFT）计算探索了整个反应的协同金属化-去质子化（CMD）过程、速率决定步骤和能量势垒。此外，还进行了一系列控制实验以探讨 C(sp 3 )-H 活化步骤的速率决定步骤和可逆性。